SCHEMBL10129792

SCHEMBL10129792

CC(=O)N[C@@H](CCc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)NC(C(=O)[C@@]1(C)CO1)C(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTRL P40313 5/20 0.57
TMPRSS11D O60235 4/20 0.57
PSMB5 P28074 15/20 0.56
PSMB2 P49721 6/20 0.56
PSMB1 P20618 4/20 0.56
PSMB8 P28062 5/20 0.56
PSMB10 P40306 5/20 0.56
PSMB9 P28065 5/20 0.56
PSMB11 A5LHX3 3/20 0.56
PSMD11 O00231 3/20 0.56
PSMD12 O00232 3/20 0.56
PSMD14 O00487 3/20 0.56
PSMA7 O14818 3/20 0.56
PSMD3 O43242 3/20 0.56
PSMC3 P17980 3/20 0.56
PSMA1 P25786 3/20 0.56
PSMA2 P25787 3/20 0.56
PSMA3 P25788 3/20 0.56
PSMA4 P25789 3/20 0.56
PSMA5 P28066 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2632714 0.93 PSMB5 (0.64) CTRLTMPRSS11DPSMB5PSMB2PSMB1
SCHEMBL2632717 0.92 CTRL (0.56) CTRLTMPRSS11DPSMB5PSMB2PSMB1
SCHEMBL2633293 0.91 PSMB5 (0.59) CTRLTMPRSS11DPSMB5PSMB2PSMB1
SCHEMBL2735645 0.86 PSMB5 (0.61) CTRLTMPRSS11DPSMB5PSMB2PSMB1
SCHEMBL10129801 0.85 CTRL (0.53) CTRLTMPRSS11DPSMB5PSMB2PSMB1
SCHEMBL2760024 0.85 PSMB5 (0.50) CTRLTMPRSS11DPSMB5PSMB2PSMB1
SCHEMBL13742992 0.85 PSMB5 (0.75) CTRLTMPRSS11DPSMB5PSMB2PSMB1
SCHEMBL14208699 0.83 PSMB5 (0.67) PSMB5PSMB2PSMB1PSMB8PSMB10
SCHEMBL13932376 0.83 PSMB5 (0.67) PSMB5PSMB2PSMB1PSMB8PSMB10
SCHEMBL10086980 0.82 CTRL (0.47) CTRLTMPRSS11DPSMB5PSMB2PSMB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120101025-A1 Compounds For Enzyme Inhibition ONYX THERAPEUTICS, INC. (US) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101025-A1 Compounds For Enzyme Inhibition ANPEP, DNPEP, CPN1 CTRL 4/4885TMPRSS11D 320/4885PSMB5 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.